Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating or preventing obstructive sleep apnea

A composition and drug technology, applied in the direction of drug combination, respiratory diseases, medical formula, etc., can solve the problems of side effects and achieve the effect of small side effects

Inactive Publication Date: 2018-07-31
REYOUNG SUZHOU BIOLOGY SCI & TECH CO LTD
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The current traditional therapy for immune inflammation is hormone therapy, but a serious drawback of hormone therapy is its side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] The first group of animal models macaques used Real-Time PCR to monitor C-reactive protein (CRP), serum circulating intercellular adhesion molecule-1 (ICAM-1), interleukin-8 (IL-8), leptin, leukocytes Actual levels of interleukin-1 (IL-1) and matrix metalloproteinase-9 (MMP-9).

[0038] This trial started to administer administration of IL-6 antagonists: for example, antibodies specifically binding to interleukin-6 or antigen-binding fragments of therapeutic candidates, through polysomnography on rhesus monkeys' nocturnal sleep snoring, number of apnea, daily Sleepiness (ESS), pharyngeal narrowing, tonsil enlargement, uvula, adenoid hyperplasia, AHI (Apnea / hypopnea index, number of obstructive apnea / hypopnea per hour of sleep time), etc. Parameters related to obstructive sleep apnea were monitored.

[0039] Real-time monitoring by RT-PCR found that after administration of IL-6 antagonists, C-reactive protein (CRP), serum circulating intercellular adhesion molecule-1 (I...

Embodiment 2

[0041] The second group of animal models macaques used Real-Time PCR to monitor the actual levels of eotaxin-3, periostin and / or carcinoembryonic antigen (CEA).

[0042] The experiment started with administration of interleukin-4 receptor (IL-4R) antagonists, such as antibodies or antigen-binding fragments that specifically bind to interleukin-4 receptors, through polysomnography on nocturnal sleep snoring and breathing in macaques. Number of pauses, daytime sleepiness (ESS), pharyngeal narrowing, tonsil enlargement, uvula, adenoid hyperplasia, AHI (Apnea / hypopnea index, obstructive apnea / hypopnea per hour of sleep Number) and other parameters related to obstructive sleep apnea were monitored.

[0043] Through RT-PCR real-time monitoring, it was found that the expression levels of eotaxin-3, periostin and / or carcinoembryonic antigen (CEA) and other genes decreased to varying degrees, and apnea and snoring detected by polysomnography The number of times all had relief in varyi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an antagonist or antibody of an interleukin-4 receptor (IL-4R) and an antigen-binding fragment thereof and / or a use of an antagonist or antibody of an interleukin-6 (IL-6) andan antigen-binding fragment thereof in preparation of a pharmaceutical composition for treating or preventing obstructive sleep apnea. The invention also discloses a pharmaceutical composition for treating or preventing obstructive sleep apnea. The active ingredients of the drug comprise an antagonist of an interleukin-4 receptor (IL-4R) or its antibody and antigen-binding fragment, or an antagonist or antibody of an interleukin-6 (IL-6) and an antigen-binding fragment thereof.

Description

technical field [0001] The present invention relates to a pharmaceutical composition for treating or preventing sleep apnea syndrome (ASA), in particular to a pharmaceutical composition for treating or preventing obstructive sleep apnea (OSAS). Background technique [0002] Snoring is a common and harmful disease that has not yet attracted people's attention. It is one of the main symptoms of sleep apnea syndrome. Due to the long-term hypoxemia and hypercapnia it causes, it can cause daytime headaches, inattention, sleepiness and other symptoms, and can induce or aggravate many diseases , such as hypertension, heart disease, cerebrovascular disease, etc. With the aging of the population and the increasing severity of obesity, the incidence of snoring is also increasing, so it is of great significance to actively treat snoring. [0003] Sleep apnea syndrome (SAS) is a potentially dangerous common disease, mainly obstructive sleep apnea syndrome (OSAS), due to complete or pa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/00A61P11/00A61K39/395A61K39/00
CPCA61K39/0005A61K39/3955A61K45/00
Inventor 谢贵各崔文俊郭树华张佳春
Owner REYOUNG SUZHOU BIOLOGY SCI & TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com